NASDAQ:ORMP

Oramed Pharmaceuticals - ORMP Stock Forecast, Price & News

$8.65

+0.31 (+3.72%)

(As of 12/2/2022 12:00 AM ET)

Add

Compare

Today's Range: $8.14
▼
$8.77
50-Day Range: $5.88
▼
$9.00
52-Week Range: $3.59
▼
$17.64

Volume: 251,729 shs
Average Volume: 311,185 shs
Market Capitalization: $338.39 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $29.00

Oramed Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 235.3% Upside
$29.00 Price Target
Short Interest: Bearish
7.44% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.91) to ($1.11) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.56 out of 5 stars

Medical Sector

926th out of 1,034 stocks

Pharmaceutical Preparations Industry

449th out of 502 stocks

3.5

Analyst's Opinion

Consensus Rating
Oramed Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $29.00, Oramed Pharmaceuticals has a forecasted upside of 235.3% from its current price of $8.65.
Amount of Analyst Coverage
Oramed Pharmaceuticals has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
7.44% of the outstanding shares of Oramed Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Oramed Pharmaceuticals has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.
Change versus previous month
Short interest in Oramed Pharmaceuticals has recently decreased by 3.64%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Oramed Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Oramed Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ORMP.

2.5

News and Social Media Coverage

News Sentiment
Oramed Pharmaceuticals has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.31 average news sentiment score of Medical companies.
Search Interest
Only 3 people have searched for ORMP on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
MarketBeat Follows
7 people have added Oramed Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Oramed Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.90% of the stock of Oramed Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 17.06% of the stock of Oramed Pharmaceuticals is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Oramed Pharmaceuticals are expected to decrease in the coming year, from ($0.91) to ($1.11) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Oramed Pharmaceuticals is -21.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Oramed Pharmaceuticals is -21.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Oramed Pharmaceuticals has a P/B Ratio of 2.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Oramed Pharmaceuticals (NASDAQ:ORMP) Stock

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

Receive ORMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ORMP Stock News Headlines

November 26, 2022 | americanbankingnews.com

Zacks Small Cap Weighs in on Oramed Pharmaceuticals Inc.'s FY2022 Earnings (NASDAQ:ORMP)

November 21, 2022 | finance.yahoo.com

ORMP: Data from NASH Phase 2 Study – Positive Takeaways

November 18, 2022 | finance.yahoo.com

Oramed Pharma Shares Fall After Additional Data From Oral Insulin Study

November 17, 2022 | finance.yahoo.com

Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH

November 16, 2022 | finance.yahoo.com

Oramed Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

November 14, 2022 | finance.yahoo.com

Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea

November 10, 2022 | finance.yahoo.com

Oramed Reports Third Quarter 2022 Financial Results

November 9, 2022 | finance.yahoo.com

Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH

October 17, 2022 | finance.yahoo.com

Oramed Pharmaceuticals (NASDAQ:ORMP) shareholders have earned a 27% CAGR over the last three years

October 14, 2022 | seekingalpha.com

ORMP Oramed Pharmaceuticals Inc.

October 7, 2022 | finance.yahoo.com

Oramed Pharmaceuticals' Oral COVID-19 Vaccine Candidate Shows Safety, Immunogenicity In Early Study

October 7, 2022 | marketwatch.com

Oramed Pharmaceuticals Sees Positive Oral Covid-19 Vaccine Data

October 7, 2022 | seekingalpha.com

Oramed oral COVID vaccine shows promise in phase 1 trial

October 7, 2022 | finance.yahoo.com

Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine

September 22, 2022 | seekingalpha.com

Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality

September 13, 2022 | nasdaq.com

Oramed Gets Positive Mid-stage Results From NASH Trial With ORMD-0801

September 13, 2022 | markets.businessinsider.com

Oramed Oral Insulin Shows Evidence For NASH Treatment

September 13, 2022 | finance.yahoo.com

Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate

September 6, 2022 | finance.yahoo.com

Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference

September 1, 2022 | finance.yahoo.com

Oramed Pharmaceuticals Inc. (ORMP)

August 25, 2022 | finance.yahoo.com

ORMP: Upcoming data from ORA-D-013-1 & NASH studies could be catalysts

August 1, 2022 | finance.yahoo.com

We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth

July 26, 2022 | markets.businessinsider.com

Oramed Accomplishes 50 Percent Enrolment In Late-Stage Oral Insulin Study

July 26, 2022 | finance.yahoo.com

Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial

July 21, 2022 | markets.businessinsider.com

Short Volatility Alert: Oramed Pharmaceuticals Inc.

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ORMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ORMP Company Calendar

Last Earnings: 1/10/2022
Today: 12/03/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 1/10/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ORMP
CUSIP: N/A
CIK: 1176309
Web: www.oramed.com
Phone: (844) 967-2633
Fax: 972-2566-0004
Employees: 12
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $29.00
High Stock Price Forecast: $35.00
Low Stock Price Forecast: $20.00
Forecasted Upside/Downside: +235.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.40)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-22,240,000.00
Net Margins: -550.52%
Pretax Margin: -1,373.37%
Return on Equity: -9.29%
Return on Assets: -8.71%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 24.55
Quick Ratio: 24.55

Sales & Book Value

Annual Sales: $2.70 million
Price / Sales: 125.33
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.92 per share
Price / Book: 2.21

Miscellaneous

Outstanding Shares: 39,120,000
Free Float: 36,416,000
Market Cap: $338.39 million
Optionable: Optionable
Beta: 2.32

Key Executives

Mr. Nadav Kidron Esq. (Age 48)
Pres, CEO & Exec. Chairman
Comp: $1.23M

Mr. David Silberman CPA (Age 38)
CFO & Treasurer
Comp: $232.47k

Mr. Joshua Hexter (Age 52)
Chief Operating & Bus. Officer
Comp: $326.94k

Dr. Miriam Kidron Ph.D. (Age 82)
Chief Scientific Officer & Director
Comp: $420.06k

Mr. Michael Rabinowitz (Age 57)
Chief Commercial Officer
Comp: $360.18k

Mr. Netanel Derovan (Age 47)
Chief Legal Officer & Company Sec.

Dr. Roy Eldor M.D.
Ph.D., Chief Medical Advisor & Member of the Scientific Advisory Board

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ORMP Stock - Frequently Asked Questions

Should I buy or sell Oramed Pharmaceuticals stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ORMP shares.
View ORMP analyst ratings or view top-rated stocks.
What is Oramed Pharmaceuticals' stock price forecast for 2023?: 2 analysts have issued 12 month price targets for Oramed Pharmaceuticals' shares. Their ORMP share price forecasts range from $20.00 to $35.00. On average, they predict the company's stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 235.3% from the stock's current price.
View analysts price targets for ORMP or view top-rated stocks among Wall Street analysts.
How have ORMP shares performed in 2022?: Oramed Pharmaceuticals' stock was trading at $14.28 on January 1st, 2022. Since then, ORMP shares have decreased by 39.4% and is now trading at $8.65.
View the best growth stocks for 2022 here.
When is Oramed Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, January 10th 2023.
View our ORMP earnings forecast.
How were Oramed Pharmaceuticals' earnings last quarter?: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced its quarterly earnings results on Monday, January, 10th. The biotechnology company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.06. The biotechnology company earned $0.67 million during the quarter, compared to the consensus estimate of $0.70 million. Oramed Pharmaceuticals had a negative net margin of 550.52% and a negative trailing twelve-month return on equity of 9.29%.

What other stocks do shareholders of Oramed Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include TransEnterix (TRXC), Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), DURECT (DRRX), OPKO Health (OPK), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN).
What is Oramed Pharmaceuticals' stock symbol?: Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."
Who are Oramed Pharmaceuticals' major shareholders?: Oramed Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Morgan Jess S & Co. Inc. (0.94%), Two Sigma Advisers LP (0.85%), Two Sigma Investments LP (0.42%), Cubist Systematic Strategies LLC (0.30%), BlackRock Inc. (0.26%) and ETF Managers Group LLC (0.24%). Insiders that own company stock include Kevin Rakin and Nadav Kidron.
View institutional ownership trends.
How do I buy shares of Oramed Pharmaceuticals?: Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Oramed Pharmaceuticals' stock price today?: One share of ORMP stock can currently be purchased for approximately $8.65.
How much money does Oramed Pharmaceuticals make?: Oramed Pharmaceuticals (NASDAQ:ORMP) has a market capitalization of $338.39 million and generates $2.70 million in revenue each year. The biotechnology company earns $-22,240,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.
How can I contact Oramed Pharmaceuticals?: Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The official website for the company is www.oramed.com. The biotechnology company can be reached via phone at (844) 967-2633, via email at ir@oramed.com, or via fax at 972-2566-0004.

This page (NASDAQ:ORMP) was last updated on 12/4/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial